105 related articles for article (PubMed ID: 19462937)
1. Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients.
Fassbender WJ; Brandenburg V; Schmitz S; Sandig D; Simon SA; Windolf J; Stumpf UC
Clin Lab; 2009; 55(3-4):144-52. PubMed ID: 19462937
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.
Gutierrez O; Isakova T; Rhee E; Shah A; Holmes J; Collerone G; Jüppner H; Wolf M
J Am Soc Nephrol; 2005 Jul; 16(7):2205-15. PubMed ID: 15917335
[TBL] [Abstract][Full Text] [Related]
3. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephrol Dial Transplant; 2009 Sep; 24(9):2792-6. PubMed ID: 19395730
[TBL] [Abstract][Full Text] [Related]
4. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women.
Burnett SM; Gunawardene SC; Bringhurst FR; Jüppner H; Lee H; Finkelstein JS
J Bone Miner Res; 2006 Aug; 21(8):1187-96. PubMed ID: 16869716
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease?
Peiskerová M; Kalousová M; Kratochvílová M; Dusilová-Sulková S; Uhrová J; Bandúr S; Malbohan IM; Zima T; Tesar V
Kidney Blood Press Res; 2009; 32(4):276-83. PubMed ID: 19797911
[TBL] [Abstract][Full Text] [Related]
6. Regulation of fibroblast growth factor-23 in chronic kidney disease.
Westerberg PA; Linde T; Wikström B; Ljunggren O; Stridsberg M; Larsson TE
Nephrol Dial Transplant; 2007 Nov; 22(11):3202-7. PubMed ID: 17567652
[TBL] [Abstract][Full Text] [Related]
7. The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays.
Durham BH; Joseph F; Bailey LM; Fraser WD
Ann Clin Biochem; 2007 Sep; 44(Pt 5):463-6. PubMed ID: 17761032
[TBL] [Abstract][Full Text] [Related]
8. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.
Larsson T; Nisbeth U; Ljunggren O; Jüppner H; Jonsson KB
Kidney Int; 2003 Dec; 64(6):2272-9. PubMed ID: 14633152
[TBL] [Abstract][Full Text] [Related]
9. Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis.
Han SH; Choi SH; Cho BJ; Lee Y; Lim S; Park YJ; Moon MK; Lee HK; Kang SW; Han DS; Kim YB; Jang HC; Park KS
Metabolism; 2010 Nov; 59(11):1656-62. PubMed ID: 20423749
[TBL] [Abstract][Full Text] [Related]
10. Instability of fibroblast growth factor-23 (FGF-23): implications for clinical studies.
Smith ER; Ford ML; Tomlinson LA; Weaving G; Rocks BF; Rajkumar C; Holt SG
Clin Chim Acta; 2011 May; 412(11-12):1008-11. PubMed ID: 21324311
[TBL] [Abstract][Full Text] [Related]
11. Determination of fibroblast growth factor 23.
Heijboer AC; Levitus M; Vervloet MG; Lips P; ter Wee PM; Dijstelbloem HM; Blankenstein MA
Ann Clin Biochem; 2009 Jul; 46(Pt 4):338-40. PubMed ID: 19564163
[TBL] [Abstract][Full Text] [Related]
12. Elevated fibroblast growth factor 23 levels as a cause of early post-renal transplantation hypophosphatemia.
Han SY; Hwang EA; Park SB; Kim HC; Kim HT
Transplant Proc; 2012 Apr; 44(3):657-60. PubMed ID: 22483462
[TBL] [Abstract][Full Text] [Related]
13. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
Imanishi Y; Kobayashi K; Kawata T; Inaba M; Nishizawa Y
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S32-7. PubMed ID: 17976083
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor 23--structure, function and role in kidney diseases.
Kocełak P; Olszanecka-Glinianowicz M; Chudek J
Adv Clin Exp Med; 2012; 21(3):391-401. PubMed ID: 23214203
[TBL] [Abstract][Full Text] [Related]
15. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.
Shigematsu T; Kazama JJ; Yamashita T; Fukumoto S; Hosoya T; Gejyo F; Fukagawa M
Am J Kidney Dis; 2004 Aug; 44(2):250-6. PubMed ID: 15264182
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor 23 in feline chronic kidney disease.
Geddes RF; Finch NC; Elliott J; Syme HM
J Vet Intern Med; 2013; 27(2):234-41. PubMed ID: 23398216
[TBL] [Abstract][Full Text] [Related]
17. The stability and variability of serum and plasma fibroblast growth factor-23 levels in a haemodialysis cohort.
Damasiewicz MJ; Lu ZX; Kerr PG; Polkinghorne KR
BMC Nephrol; 2018 Nov; 19(1):325. PubMed ID: 30428848
[TBL] [Abstract][Full Text] [Related]
18. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients.
Koiwa F; Kazama JJ; Tokumoto A; Onoda N; Kato H; Okada T; Nii-Kono T; Fukagawa M; Shigematsu T;
Ther Apher Dial; 2005 Aug; 9(4):336-9. PubMed ID: 16076378
[TBL] [Abstract][Full Text] [Related]
19. Novel regulators of phosphate homeostasis and bone metabolism.
Jüppner H
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S3-22. PubMed ID: 17976082
[TBL] [Abstract][Full Text] [Related]
20. FGF-23 in patients with end-stage renal disease on hemodialysis.
Imanishi Y; Inaba M; Nakatsuka K; Nagasue K; Okuno S; Yoshihara A; Miura M; Miyauchi A; Kobayashi K; Miki T; Shoji T; Ishimura E; Nishizawa Y
Kidney Int; 2004 May; 65(5):1943-6. PubMed ID: 15086938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
